MG1MA3(MG1MA3) - 药物靶点：MAGEA3_专利_临床

概要

基本信息

药物类型

重组载体疫苗、通用抗原疫苗、治疗性疫苗

别名

Marabex

+ [5]

靶点

MAGEA3

作用机制

MAGEA3抑制剂(黑色素瘤相关抗原3抑制剂)

治疗领域

肿瘤呼吸系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

黑色素瘤非小细胞肺癌实体瘤+ [1]

原研机构

McMaster University

在研机构-

非在研机构

Turnstone Biologics Corp.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 MG1MA3 相关的临床试验

NCT03773744 / Withdrawn临床1期

A Phase 1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing MAGE-A3 (MG1-MAGEA3) With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Immune Modulating Therapy in Patients With Metastatic Melanoma or Previously Treated Cutaneous Squamous Cell Carcinoma

This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic Melanoma patients.

开始日期2020-02-15

申办/合作机构

Turnstone Biologics, Inc.

NCT02879760 / Completed临床1/2期

A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)

This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at least 1 cycle of platinum based chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy.

开始日期2017-03-08

申办/合作机构

Turnstone Biologics, Inc.

100 项与 MG1MA3 相关的临床结果

登录后查看更多信息

100 项与 MG1MA3 相关的转化医学

登录后查看更多信息

100 项与 MG1MA3 相关的专利（医药）

登录后查看更多信息

100 项与 MG1MA3 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床2期	-	Turnstone Biologics Corp.	2020-02-15
鳞状细胞癌	临床2期	-	Turnstone Biologics Corp.	2020-02-15
非小细胞肺癌	临床2期	加拿大	Turnstone Biologics Corp.	2017-03-08
实体瘤	临床2期	加拿大	-	2014-10-22